Ataxia Canada is pleased to share an important research milestone for the Friedreich’s ataxia community. Lexeo Therapeutics has announced the publication of Phase I/II clinical data for LX2006, an investigational gene therapy for Friedreich’s ataxia, in the peer-reviewed journal JAMA Cardiology. The publication combines data from 17 participants enrolled in...
We would like to inform you of an important update regarding access to SKYCLARYS™ (omaveloxolone), the first and only treatment approved in Canada for Friedreich’s ataxia (FA). Negotiations between Biogen Canada and the Pan-Canadian Pharmaceutical Alliance (APP/pCPA) regarding SKYCLARYS have concluded without an agreement. This situation is causing a significant...
Important step forward for people living with Friedreich ataxia in Quebec Montréal, Québec – June 3rd 2026 , Ataxia Canada welcomes the recent re-evaluation by the Institut national d’excellence en santé et en services sociaux (INESSS), which recognizes the therapeutic value of SKYCLARYS™ (omaveloxolone) for individuals living with Friedreich ataxia (FA)....
Gene Therapy Update for Friedreich’s Ataxia What patients and families should know (March 2026) Who is Lexeo Therapeutics? Lexeo Therapeutics is a biotechnology company developing gene therapies for heart disease, including heart involvement caused by Friedreich’s ataxia (FA)—a major cause of illness and premature death in FA. What treatment is...
Researchers at The Neuro (Montreal Neurological Institute-Hospital) are currently evaluating a non-invasive electrical brain stimulation technique to temporarily relieve symptoms of Friedreich’s ataxia (FA). This international clinical study, conducted in Canada exclusively at The Neuro is exploring the use of transcranial direct current stimulation (tDCS) to reactivate brain circuits affected...
For Adolescent Patients and Parents/Caregivers of Pediatric Patients The BRAVE Study is evaluating a potential treatment option for Friedreich Ataxia. If your child has been diagnosed with Friedreich Ataxia (FA), they may be eligible for the BRAVE Study. About the BRAVE Study. The BRAVE Study is evaluating how safe a...
Message to the Friedreich Ataxia Community October 7, 2025 Dear Advocacy Partners and FA community members, This morning, we were pleased to share positive interim clinical data for LX2006, our investigational gene therapy, that includes both cardiac and neurological outcome measures. LX2006 (AAVrh10hFXN) is currently being studied in the Lexeo-sponsored...